These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30219843)

  • 1. Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings.
    Robertson KR; Jiang H; Kumwenda J; Supparatpinyo K; Marra CM; Berzins B; Hakim J; Sacktor N; Campbell TB; Schouten J; Mollan K; Tripathy S; Kumarasamy N; La Rosa A; Santos B; Silva MT; Kanyama C; Firhnhaber C; Murphy R; Hall C; Marcus C; Naini L; Masih R; Hosseinipour MC; Mngqibisa R; Badal-Faesen S; Yosief S; Vecchio A; Nair A;
    Clin Infect Dis; 2019 May; 68(10):1733-1738. PubMed ID: 30219843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study.
    Robertson K; Jiang H; Kumwenda J; Supparatpinyo K; Evans S; Campbell TB; Price R; Tripathy S; Kumarasamy N; La Rosa A; Santos B; ; Silva MT; Montano S; Kanyama C; Faesen S; Murphy R; Hall C; Marra CM; Marcus C; Berzins B; Allen R; Housseinipour M; Amod F; Sanne I; Hakim J; Walawander A; Nair A;
    Clin Infect Dis; 2012 Sep; 55(6):868-76. PubMed ID: 22661489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction.
    Robertson KR; Oladeji B; Jiang H; Kumwenda J; Supparatpinyo K; Campbell TB; Hakim J; Tripathy S; Hosseinipour MC; Marra CM; Kumarasamy N; Evans S; Vecchio A; La Rosa A; Santos B; Silva MT; Montano S; Kanyama C; Firnhaber C; Price R; Marcus C; Berzins B; Masih R; Lalloo U; Sanne I; Yosief S; Walawander A; Nair A; Sacktor N; Hall C;
    Clin Infect Dis; 2019 May; 68(10):1739-1746. PubMed ID: 30137250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
    Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
    AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.
    Coban H; Robertson K; Smurzynski M; Krishnan S; Wu K; Bosch RJ; Collier AC; Ellis RJ
    AIDS; 2017 Jul; 31(11):1565-1571. PubMed ID: 28471765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.
    Nichols SL; Bethel J; Kapogiannis BG; Li T; Woods SP; Patton ED; Ren W; Thornton SE; Major-Wilson HO; Puga AM; Sleasman JW; Rudy BJ; Wilson CM; Garvie PA;
    J Neurovirol; 2016 Apr; 22(2):218-30. PubMed ID: 26463526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271.
    Robertson K; Jiang H; Evans SR; Marra CM; Berzins B; Hakim J; Sacktor N; Silva MT; Campbell TB; Nair A; Schouten J; ; Kumwenda J; Supparatpinyo K; Tripathy S; Kumarasamy N; la Rosa A; Montano S; Mwafongo A; Firnhaber C; Sanne I; Naini L; Amod F; Walawander A;
    J Neurovirol; 2016 Aug; 22(4):472-8. PubMed ID: 26733457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.
    Arenas-Pinto A; Stöhr W; Jäger HR; Haddow L; Clarke A; Johnson M; Chen F; Winston A; Godi C; Thust S; Trombin R; Cairns J; Solanky BS; Golay X; Paton NI;
    Clin Infect Dis; 2016 Jul; 63(2):257-64. PubMed ID: 27143662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals.
    Kalayjian RC; Robertson KR; Albert JM; Fichtenbaum CJ; Brown TT; Taiwo BO;
    J Acquir Immune Defic Syndr; 2019 Jun; 81(2):e49-e54. PubMed ID: 30939531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive Impairment in Well-Controlled HIV-Infected Patients: A Cross-Sectional Study.
    Portilla I; Reus S; León R; van-der Hofstadt C; Sánchez J; López N; Boix V; Merino E; Portilla J
    AIDS Res Hum Retroviruses; 2019 Jul; 35(7):634-641. PubMed ID: 30880401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings.
    Robertson K; Kumwenda J; Supparatpinyo K; Jiang JH; Evans S; Campbell TB; Price RW; Murphy R; Hall C; Marra CM; Marcus C; Berzins B; Masih R; Santos B; Silva MT; Kumarasamy N; Walawander A; Nair A; Tripathy S; Kanyama C; Hosseinipour M; Montano S; La Rosa A; Amod F; Sanne I; Firnhaber C; Hakim J; Brouwers P;
    J Neurovirol; 2011 Oct; 17(5):438-47. PubMed ID: 21786076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy.
    Letendre S; Bharti A; Perez-Valero I; Hanson B; Franklin D; Woods SP; Gianella S; de Oliveira MF; Heaton RK; Grant I; Landay AL; Lurain N;
    Clin Infect Dis; 2018 Aug; 67(5):770-777. PubMed ID: 29506084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psycho-behavioral factors associated with neurocognitive performance among people living with HIV on antiretroviral therapy in Accra, Ghana.
    Asiedu N; Kretchy I; Asampong E
    Afr Health Sci; 2020 Jun; 20(2):487-596. PubMed ID: 33163015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda.
    Vecchio A; Robertson K; Saylor D; Nakigozi G; Nakasujja N; Kisakye A; Batte J; Mayanja R; Anok A; Reynolds SJ; Quinn TC; Gray R; Wawer MJ; Sacktor N; Rubin LH
    J Acquir Immune Defic Syndr; 2020 Aug; 84(5):534-542. PubMed ID: 32692113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latent Toxoplasma Infection and Higher Toxoplasma gondii Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults.
    Bharti AR; McCutchan A; Deutsch R; Smith DM; Ellis RJ; Cherner M; Woods SP; Heaton RK; Grant I; Letendre SL
    Clin Infect Dis; 2016 Dec; 63(12):1655-1660. PubMed ID: 27794019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief Report: Intracellular Cystatin B Levels Are Altered in HIV-Infected Participants With Respect to Neurocognitive Status and Antiretroviral Therapy.
    Opsteen S; Moylan D; Taiwo BO; Robertson KR; Overton ET; Cutter GR; Sabbaj S; Heath SL; Shacka JJ
    J Acquir Immune Defic Syndr; 2022 Dec; 91(5):485-489. PubMed ID: 36083516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
    Reid A; Stöhr W; Walker AS; Williams IG; Kityo C; Hughes P; Kambugu A; Gilks CF; Mugyenyi P; Munderi P; Hakim J; Gibb DM;
    Clin Infect Dis; 2008 Apr; 46(8):1271-81. PubMed ID: 18444867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Declining Prevalence of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy-Treated Individuals With HIV.
    Mastrorosa I; Pinnetti C; Brita AC; Mondi A; Lorenzini P; Del Duca G; Vergori A; Mazzotta V; Gagliardini R; Camici M; De Zottis F; Fusto M; Plazzi MM; Grilli E; Bellagamba R; Cicalini S; Antinori A
    Clin Infect Dis; 2023 Feb; 76(3):e629-e637. PubMed ID: 35982541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
    Collier D; Iwuji C; Derache A; de Oliveira T; Okesola N; Calmy A; Dabis F; Pillay D; Gupta RK;
    Clin Infect Dis; 2017 Apr; 64(8):1006-1016. PubMed ID: 28329393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
    Mugavero MJ; May M; Ribaudo HJ; Gulick RM; Riddler SA; Haubrich R; Napravnik S; Abgrall S; Phillips A; Harris R; Gill MJ; de Wolf F; Hogg R; Günthard HF; Chêne G; D'Arminio Monforte A; Guest JL; Smith C; Murillas J; Berenguer J; Wyen C; Domingo P; Kitahata MM; Sterne JA; Saag MS; ; ; ;
    J Acquir Immune Defic Syndr; 2011 Nov; 58(3):253-60. PubMed ID: 21857357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.